Endowment Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-928
Closed -$9K 119
2022
Q2
$9K Buy
928
+100
+12% +$1.26K 0.01% 113
2022
Q1
$14K Buy
+828
New +$14.4K 0.01% 123

Other funds holding DFTX

Endowment Wealth Management's DFTX Position: Q3 2022 in Review

Endowment Wealth Management sold out of Definium Therapeutics (DFTX) in Q3 2022, closing a stake of 928 shares — an estimated $9K sold.

Endowment Wealth Management first reported a position in DFTX in Q1 2022 and held it in 2 quarters. The position peaked at $14K in Q1 2022. 101 funds tracked by Wall St. Rank hold DFTX as of Q3 2022.

  • Endowment Wealth Management reported no remaining Definium Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Endowment Wealth Management sold 928 Definium Therapeutics shares in Q3 2022, an estimated $9K.
  • Endowment Wealth Management first reported a position in Definium Therapeutics in Q1 2022 and held it in 2 quarters.
  • Endowment Wealth Management's Definium Therapeutics position peaked at $14K in Q1 2022.
  • 101 funds tracked by Wall St. Rank held Definium Therapeutics as of Q3 2022.

Based on Endowment Wealth Management's 13F filing for Q3 2022, filed 14 Nov 2022.